A Phase II Safety and Tolerability Study With SEN0014196

NCT01521585 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

144

Enrollment

INDUSTRY

Sponsor class

Conditions

Huntington's Disease

Interventions

DRUG: SEN0014196
DRUG: SEN0014196
DRUG: Placebo

Sponsor

Siena Biotech S.p.A.